KMTS

Kestra is a freshly-public (March 2025 IPO) single-product med-device story built entirely on the ASSURE wearable cardioverter defibrillator. The top line is genuinely impressive: FY2025 revenue of $59.8M grew 115.1% YoY (off $27.8M in FY2024), and gross profit swung to $24.2M for a 40.5% gross margin — evidence the leased-device model is starting to scale economically rather than just buying revenue. The IPO also left a clean, well-capitalized balance sheet: $238M cash against just $41.1M long-term debt, $205M equity, and a conservative 0.44x liabilities/equity. That cash is the single most important fact here — it de-risks the next roughly two years.

The problem is everything below the gross-profit line. Operating income was -$106M (a -177.8% operating margin) and net loss widened to -$114M, with operating cash flow of -$77.6M and capex of $22.9M, so free-cash burn is running near $100M a year. On ~$238M of cash that is a ~2-year runway, and management explicitly flags it 'may need to raise equity or debt financing' — dilution or new leverage is a when, not an if, and the -$520M accumulated deficit shows how capital-hungry this model is. Layer on a self-disclosed material weakness in internal controls over financial reporting, total dependence on one product for reimbursement-driven revenue, a limited operating history, and Bain Capital control whose 'interests may conflict with yours,' and the risk profile is firmly speculative.